
3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
Publication
, Conference
Gettinger, SN; Hellmann, MD; Shepherd, FA; Antonia, SJ; Brahmer, J; Chow, LQ; Goldman, J; Juergens, R; Borghaei, H; Ready, NE; Gerber, DE ...
Published in: European Journal of Cancer
September 2015
Duke Scholars
Published In
European Journal of Cancer
DOI
ISSN
0959-8049
Publication Date
September 2015
Volume
51
Start / End Page
S632 / S632
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Gettinger, S. N., Hellmann, M. D., Shepherd, F. A., Antonia, S. J., Brahmer, J., Chow, L. Q., … Rizvi, N. (2015). 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. In European Journal of Cancer (Vol. 51, pp. S632–S632). Elsevier BV. https://doi.org/10.1016/s0959-8049(16)31737-3
Gettinger, S. N., M. D. Hellmann, F. A. Shepherd, S. J. Antonia, J. Brahmer, L. Q. Chow, J. Goldman, et al. “3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses.” In European Journal of Cancer, 51:S632–S632. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(16)31737-3.
Gettinger SN, Hellmann MD, Shepherd FA, Antonia SJ, Brahmer J, Chow LQ, et al. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. In: European Journal of Cancer. Elsevier BV; 2015. p. S632–S632.
Gettinger, S. N., et al. “3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses.” European Journal of Cancer, vol. 51, Elsevier BV, 2015, pp. S632–S632. Crossref, doi:10.1016/s0959-8049(16)31737-3.
Gettinger SN, Hellmann MD, Shepherd FA, Antonia SJ, Brahmer J, Chow LQ, Goldman J, Juergens R, Borghaei H, Ready NE, Gerber DE, Nathan F, Shen Y, Harbison CT, Rizvi N. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. European Journal of Cancer. Elsevier BV; 2015. p. S632–S632.

Published In
European Journal of Cancer
DOI
ISSN
0959-8049
Publication Date
September 2015
Volume
51
Start / End Page
S632 / S632
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis